This website is intended for UK healthcare professionals.
The Adverse Event Reporting and a link to the Prescribing Information can be found at the bottom of the page.

Equasym XL logo

Equasym® XL (methylphenidate hydrochloride modified release capsules) is indicated as part of a comprehensive treatment programme for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over when remedial measures alone prove insufficient.1

Treatment must be under the supervision of a specialist in childhood behavioural disorders.1

Request a call from a Takeda representative to discuss Equasym XL

Icon

Request here

View the Equasym XL patient booklet

Icon

A booklet for child & adolescent patients who have been prescribed Equasym XL explaining what the medication is, what they can expect from it, and how it should be taken.

Download here

References

  1. Equasym XL. Summary of Product Characteristics.

Takeda

Elvanse® Prescribing Information

Equasym® XL Prescribing Information

Intuniv® Prescribing Information

For Adverse Event Reporting related to
Elvanse and Equasym XL:

Adverse events should be reported to the Medicines and Healthcare products Regulatory Agency.
Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Takeda at: AE.GBR‑IRL@takeda.com.

For Adverse Event Reporting related to
Intuniv:

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Takeda at: AE.GBR‑IRL@takeda.com.

Terms of Use

Privacy Policy

Contact Us

C-APROM/GB/ELVS/0042 | March 2023